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Abstract
Members of the epidermal growth factor receptor family (EGFR/Erb1, Erb2/HER2, ErbB3/HER3 
and ErbB4/HER4) are key targets for inhibition in cancer therapy1. Critical for activation is the 
formation of an asymmetric dimer by the intracellular kinase domains, in which the C-terminal 
lobe (C-lobe) of one kinase domain induces an active conformation in the other2. The cytoplasmic 
protein Mig6 (Mitogen-induced gene 6) interacts with and inhibits the kinase domains of EGFR 
and ErbB23–5. Crystal structures of complexes between the EGFR kinase domain and a fragment 
of Mig6 show that a ~25-residue epitope (segment 1) from Mig6 binds to the distal surface of the 
C-lobe of the kinase domain. Biochemical and cell-based analyses confirm that this interaction 
contributes to EGFR inhibition by blocking the formation of the activating dimer interface. A 
longer Mig6 peptide that is extended C-terminal to segment 1 has increased potency as an 
inhibitor of the activated EGFR kinase domain, while retaining a critical dependence on segment 
1. We show that signaling by EGFR molecules that contain constitutively active kinase domains 
still requires formation of the asymmetric dimer, underscoring the importance of dimer interface 
blockage in Mig6-mediated inhibition.
Prior to activation, the EGFR kinase domain is in an autoinhibited conformation which 
resembles that of inactive cyclin-dependent kinases (CDKs) and the Src family kinases2,6. 
Conversion to the active form requires interactions between the distal surface of the C-lobe 
of one kinase domain and the N-terminal lobe (N-lobe) of the other in the asymmetric 
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activating dimer2. This conformational change resembles closely the activation switch 
induced in CDKs by cyclins7, even though the C-lobe of the EGFR kinase domain is 
structurally unrelated to cyclins.
If the cyclin/CDK-like asymmetric dimer is indeed critical for EGFR activation, then the 
modulation of this interaction might underlie naturally occurring mechanisms of EGFR 
regulation. We looked for protein inhibitors of EGFR that are known to function by 
interacting with the intracellular portions of the receptor. One such protein is Mig6 (or 
receptor associated late transducer, RALT, the gene for which is also named gene 33), which 
is a feedback inhibitor of both EGFR and ErbB23,5. Mig6 inhibits EGFR-mediated signals in 
mouse skin8, and deletion of the Mig6 gene leads to hyper-activation of EGFR 9,10.
The N-terminal region of Mig6 is not implicated in EGFR inhibition (Fig. 1a). The C-
terminal region shows sequence similarity only to a non-catalytic region of the ACK1 
tyrosine kinase (Fig 1a), which also binds to the EGFR cytoplasmic domain11. A segment 
within this region of Mig6 (residues 323–372) is critical for ErbB2 and EGFR binding (Fig. 
1a)12,13. We determined the crystal structure of a 60-residue fragment spanning this segment 
(residues 315–374) bound to the EGFR kinase domain (Supplemental Material). This 
structure and structures of EGFR complexed to two overlapping 40- and 25-residue 
fragments (residues 325–364 and 340–364) define a 25-residue epitope of Mig6 that is 
sufficient for binding to the EGFR kinase domain (residues 337–361, denoted 
Mig6segment 1). The structure of the 40-residue peptide complex has been determined at 2.9 
Å resolution.
The EGFR kinase domain bound to Mig6segment 1 adopts the Src/CDK-like inactive 
conformation, and not the active conformation normally seen in crystals of the kinase 
domain (Fig. 1b)2,6. The interface, which buries 1800 Å2 of surface area, involves an 
extended conformation of the Mig6 peptide and disparate binding elements on the kinase 
domain (Fig. 1b and c; Supplemental Material). Mig6segment 1 lies within a shallow 
depression on the distal surface of the C-lobe of the kinase domain, formed by helices αG 
and αH and the loops connecting helices αF-αG, αG-αH and αH-αI. The interations are 
mainly polar, although a few hydrophobic residues from helix αH contribute to the interface.
The footprint of Mig6segment 1 on the kinase domain overlaps the cyclin-like face of the 
kinase domain in the asymmetric kinase domain dimer and so binding of Mig6 to an EGFR 
kinase domain will prevent it from acting as a cyclin-like activator for other kinase domains 
(Fig. 1 and 4d). Residues in EGFR located at the Mig6segment 1 binding interface are 
conserved2, suggesting that Mig6 will also bind to other EGFR family members.
Mig6segment 1 binds to the EGFR kinase domain with micromolar affinity. The dissociation 
constant for a 30-residue fluorescein-labeled Mig6 peptide (residues 334–363, spanning the 
entire binding epitope of segment 1) is 13.0+/−1.3 μM (Fig. 2a and Supplemental Table 1). 
Val924 in the C-lobe of the kinase domain is located in the center of the asymmetric kinase 
domain dimer interface and also participates in the interaction between the kinase domain 
and Mig6segment 1 (Fig. 1b and c)2. A V924R mutation in the kinase domain abolishes 
peptide binding (Fig. 2a). Met346, Phe352 and Tyr358 in Mig6 are within the kinase/
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Mig6segment 1 interface (Fig. 1c), and mutation of any of these residues also abrogates 
binding (Fig. 2b).
The EGFR kinase domain has very low activity in solution, but is activated upon increasing 
its local concentration by tethering it to lipid vesicles, which promotes the formation of the 
asymmetric dimer2. Various Mig6 peptides which contain segment 1 inhibit the activity of 
the kinase domain attached to lipid vesicles, with IC50 values of ~10 μM (Fig. 2c). A 25-
residue peptide (residues 340–364), which lacks 3 residues in the N-terminal portion of 
Mig6segment 1, is much less potent (Fig. 2c and Supplemental Material). Peptides that contain 
mutations which disrupt the binding interface (M346A, F352A and Y358A) do not inhibit 
kinase activity significantly. An EGFR kinase domain bearing an I682Q mutation is not 
stimulated by concentration at the membrane because it is unable to form the asymmetric 
dimer2. The basal activity of this mutant in solution is not inhibited by Mig6segment 1, which 
has the same binding affinity for this mutation as for the wild type kinase domain (Fig. 2a 
and Supplemental Figure 3). Thus, Mig6segment 1 is only able to inhibit the kinase domain in 
the context of asymmetric dimer formation.
We tested the inhibition of EGFR autophosphorylation by full length Mig6 in a cell-based 
assay. Co-expression of the wild type Mig6 with EGFR decreases the EGF-induced 
autophosphorylation of EGFR, whereas individual introduction of mutations in 
Mig6segment 1 (M346A, F352A or Y358A) abolishes this effect (Fig. 2d), confirming that 
segment 1 is important for inhibition of EGFR by full length Mig6.
An intriguing property of Mig6 is its ability to bind more tightly to activated EGFR than to 
the unliganded receptor3,5,12. Mig6segment 1 alone cannot confer this property, because the 
kinase residues that interact with it do not change conformation upon activation2,6,14. The C-
terminus of Mig6segment 1 is located within a channel leading into the kinase active site (Fig. 
1b), utilized by peptidic inhibitors of protein kinases that interact directly with the active 
sites15,16. The region of Mig6 that is C-terminal to segment 1 (segment 2, Fig. 1a) contains a 
region of strong homology to ACK13,5,11. Since Mig6 and ACK1 are both sensitive to the 
activation state of EGFR3,5,11,12, there may be specific interactions between segment 2 and 
the activation loop and/or the N-lobe of the kinase domain.
To test the role of segment 2, we produced a longer peptide (residues 336–412, 
Mig6segment 1–2), and analyzed its effect on a variant of the EGFR kinase domain that 
contains a mutation (L834R) that renders it constitutively active in the absence of 
concentration on vesicles2. Mig6segment 1–2 inhibits this mutant kinase domain with an IC50 
value of ~200 nM (Fig. 3a). Mig6segment 1–2 bearing a mutation within segment 1 (Y358A) 
inhibited L834R much less efficiently (IC50 ~5 μM). Mig6segment 1 (the 30-residue peptide) 
did not inhibit this mutant kinase, consistent with its dimerization-independent activity. 
Interestingly, Mig6segment 1–2 appears to be much less potent in inhibiting the basal activity 
of the wild type kinase domain in solution, and Mig6segment 1–2 bearing a mutation in 
segment 1 (Y358A) does not show any inhibition under the same conditions (Fig. 3b). These 
results suggest that segment 2 is responsible for the inhibition of the activated EGFR kinase 
domain, and that both segments 1 and 2 are important for the high potency of inhibition.
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Could Mig6 function by binding primarily to the activated kinase in an asymmetric kinase 
domain dimer, and not to the cyclin-like activator kinase? The Mig6segment 1 interaction 
would then be important for anchorage of Mig6 to EGFR, but not directly relevant for 
shutting down kinase activity. Such a role may be operative in autoinhibition of ACK1, the 
kinase domain of which has a conserved segment 1 binding surface, with the Mig6 
homologous segments present within the same protein (Supplemental Material). We expect, 
however, that the asymmetric EGFR dimer will dissociate, and that activated kinase 
molecules can subsequently serve as cyclin-like activators. This may facilitate the lateral 
propagation of EGFR activation, which can spread across the cell surface even when EGF is 
localized to a small region17,18. The interaction between Mig6segment 1 and the kinase 
domain would block further transmission of the activating signal.
To exam this potential, we co-transfected cells with two variants of EGFR. One form 
(EGFRactivator) resembles ErbB3 in that it is catalytically inactive (the catalytic base, Asp 
813, is mutated to Asn) but can serve as a cyclin-like activator. To promote its interaction 
with Mig6 we introduced the L834R mutation, which destabilizes the inactive conformation, 
into EGFRactivator. To prevent EGFRactivator from assuming the “activated” position in the 
asymmetric dimer we also introduced the I682Q mutation2. The second EGFR variant 
(EGFRactivatable) is catalytically active, but has the V924R mutation, which prevents it from 
serving as an activator2. We tested the effects of Mig6 on EGFR phosphorylation in co-
transfections with these two variants. The results show that EGFRactivator can activate 
EGFRactivatable in the presence of EGF (Fig. 4a), consistent with our previous findings2. Co-
transfection of Mig6 with EGFRactivator and EGFRactivatable suppresses this activation (Fig. 
4a). Mig6segment 1 does not bind to the kinase domain bearing the V924R mutation, and an 
intact Mig6segment 1 is required for inhibition of EGFR in cellular assays (Fig. 2). We 
therefore interpret the results of the triple transfection experiment (Fig. 4a) to mean that 
Mig6 binds to EGFRactivator and prevents the activation of EGFRactivatable.
Full-length EGFR bearing the activating L834R mutation is not fully phosphorylated in 
cells19,20, suggesting that the formation of the asymmetric dimer is still required for robust 
autophosphorylation even when the kinase domain is rendered constitutively active. We 
confirmed this by introducing the V924R mutation, which prevents the kinase domain from 
serving as the cyclin-like activator, into EGFR with a constitutively active kinase domain 
(L834R/V924R). EGFR(L834R/V924R) fails to undergo autophosphorylation (Fig. 4b), 
although the kinase activity of this double mutant is comparable to that of the kinase domain 
bearing the single activating mutation (L834R) (Supplemental Figure 6). EGF-stimulated 
autophosphorylation is restored when this double mutant is co-transfected with the kinase-
dead EGFRactivator (Fig. 4b). These results further underscore the importance of blockage of 
the asymmetric dimer interface by Mig6, as it can prevent both the activation of kinase 
domains and downstream signaling by activated kinase domains.
Our results demonstrate that Mig6 uses a double-headed mechanism for inhibiting EGFR, 
with the blockage of the asymmetric cyclin/CDK-like dimer being a particularly interesting 
aspect of the inhibition (Fig. 4c). This mechanism provides direct confirmation for the 
critical role of the asymmetric kinase domain dimer in the activation of EGFR family 
receptors. In addition, our results suggest an approach for the development of a new class of 
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inhibitors that act by binding to the cyclin-like face of the C-lobe of the kinase domains of 
this family. This region is not conserved in other protein kinases, and so such inhibitors may 




All the Mig6 peptides used in this study are listed in Supplemental Table 1. The 60-residue 
peptide was expressed as a GST-fusion in Escherichia coli BL21 (DE3) by using pGEX6p1 
(Amersham) (BamHI/XhoI) and purified using a glutathione sepharose column. The protein 
was treated with the PreScission protease to release the Mig6 peptide, which was further 
purified using a Hitrap SP column (Amersham). The longer peptides (336–412 and 336–
412(Y358A)) were cloned as Trp ΔLE fusions and expressed as inclusion bodies as 
described previously21. To prevent cleavage of the Mig6 peptides by subsequent cyanogen 
bromide treatment the single methionine in these peptides (M346) was mutated to leucine. 
This mutation does not affect the binding to the EGFR kinase domain significantly 
(Supplemental Fig. 4). The fusion proteins were cleaved with cyanogen bromide and the 
released Mig6 peptides were purified. All other Mig6 peptides were synthesized using solid 
phase peptide synthesis via the Fmoc strategy with Wang resin on a Protein Technologies 
PS3 synthesizer. The peptide identities were confirmed by mass spectrometry.
Structure determination
The EGFR kinase domain constructs used are identical to those used previously2, except for 
the K799E mutant, which includes six fewer residues at the N-terminus (spanning residues 
678–998 of EGFR), and proteins were purified as described2. The wild type kinase domain 
was first co-crystallized with the 60-residue Mig6 peptide and the structure was determined 
at 3.5 Å resolution. This revealed that a ~25-residue segment of the peptide is bound to the 
distal surface of the C-lobe of the EGFR kinase domain and that the rest of the peptide is 
disordered (Supplemental Fig. 1a). A 25-residue peptide (residues 340–364 in Mig6) was 
designed based on the initial structure and cocrystallized with both the wild type and a 
mutant (K799E) form of the EGFR kinase domain. The K799E mutation does not affect the 
conformation of the kinase domain or its interaction with Mig6segment 1 (Supplemental 
Figure 5), but crystals of this mutant kinase domain in complex with the peptide diffracted 
X-rays to higher resolution. The structure shows that this 25-residue peptide lacks the N-
terminal part of the kinase binding epitope (Supplemental Figure 1b). This peptide was then 
extended to include residues 325–364 in Mig6 (the 40-residue peptide) and co-crystallized 
with the EGFR (K799E) kinase domain. The structure of this peptide/kinase domain 
complex was determined at 2.9 Å. There are four kinase domains in the asymmetric unit, all 
of which adopt the same conformation. Two of the four kinase domains are bound to the 
Mig6 peptide, and the Mig6 binding surfaces of the other two are occupied by crystal 
contacts. Crystallization conditions, data collection and structural refinement statistics are 
summarized in Supplemental Table 2.
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Fluorescein-labeled 30-residue wild type, M346L, M346A, F352A and Y358A Mig-6 
peptides were diluted to final concentrations of 5, 8, 3.1, 3.5 and 2.7 μM in a buffer 
containing 10 mM Tris, 50 mM NaCl and 2 mM DTT, pH 7.5. These peptides in the cuvette 
were then titrated with the wild type or mutant forms of the EGFR kinase domain at 20 °C. 
For the competition assays, the labeled 30mer wild type peptide (5 μM) and kinase domain 
(60 μM) were mixed and titrated with unlabeled competitor peptides. The fluorescence 
anisotropy at each titration step was monitored. The I682Q and K799E mutant kinases used 
in the binding assays contain the N-terminal 6xHis tag and linker fragment before the kinase 
domain, whereas this N-terminal fragment in the wild type and V924R mutant kinases was 
removed by Tobacco Etch Virus protease treatment.
Kinase assays
The assays were conducted as described previously2. The substrate peptide was kept at 1 
mM in all the experiments. The reported rates are the initial velocities normalized by the 
kinase concentrations. The wild type kinase concentrations in the vesicle-based and 
solution-based assays were 3.5 and 14 μM respectively. Preliminary experiments showed 
that peptide 336–412 (Mig6segment 1–2) inhibited the L834R mutant kinase much more 
strongly and also caused precipitation when both the kinase and the peptide were at high 
concentrations. We therefore reduced the concentration of L834R in the assays to 200 nM. 
The higher intrinsic activity of this mutant and usage of MnCl2 at 10 mM instead of MgCl2 
allowed us to measure kinase activity at such a low kinase concentration22.
Cell-based assays
Cos-7 cells were co-transfected using Fugene 6 (Roche) with the N-terminal FLAG-tagged 
EGFR-pcDNA3.1 constructs (as used before2) and the wild type or mutants of the Mig6 
genes with a C-terminal Myc tag (also in pcDNA3.1). Cells were cultured for 36 hours after 
transfection and serum-starved for 12 hours. Cells were treated with EGF (50 ng/ml) for ~5 
minutes at 37 °C, lysed and subjected to Western blot analyses. The levels of total EGFR, 
EGFR autophosphorylation and Mig6 were probed using the anti-EGFR antibody SC03 
(Santa Cruz), anti-phosphotyrosine antibody 4G10 (Upstate) and an anti-Myc antibody (Cell 
Signaling), respectively.
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Figure 1. Structure of the EGFR kinase domain/Mig6segment 1
a, Schematic diagram of human Mig6 primary structure. Regions of interest, including the 
previously defined EGFR/ErbB2 binding region4,5,12, are boxed and labeled. b, Two 
orthogonal views of the EGFR kinase domain/Mig6segment 1 complex. A channel which 
peptide inhibitors of some other kinases are docked is indicated15,16. The electron density 
around Mig6segment 1 in the right panel is contoured at 3σ and is from a simulated annealing 
omit map with coefficients (|Fo|-|Fc|)eiαC, where the calculated structure factors are 
generated from a model that does not contain Mig6. c, Detailed view of the interface 
between the EGFR kinase domain and Mig6segment 1. Hydrogen bonds are represented by 
dashed lines. d, Comparison of the Mig6segment 1 binding interface and the kinase domain 
asymmetric dimer interface on the distal surface of the kinase C-lobe. A large portion of the 
surface is shared by the two interfaces (outlined), and it is clear that binding of the EGFR 
kinase domain by Mig6segment 1 would block the formation of the asymmetric activating 
dimer. (c) and (d) are in similar orientations as that in the right panel of (b).
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Figure 2. Binding and inhibition of EGFR by Mig6segment 1
a, Titrations of the wild type EGFR kinase domain and the V924R and I682Q mutants to the 
30-residue (residues 334–363) fluorescein-labeled Mig6 peptide. b, Titrations of the wild 
type EGFR kinase domain to the wild type and three mutant 30-residue fluorescein-labeled 
peptides. n.d. denotes “not determined” (KD values cannot be determined reliably). c, 
Inhibition of the activity of the EGFR kinase domain by peptides spanning Mig6segment 1 in 
the vesicle-based kinase assay. The 60-, 40- and 30-residue peptides contain the entire 
binding epitope of segment 1, while the 25-residue peptide lacks the N-terminal 3 residues. 
The mutations were introduced in the 30-residue peptide. See Supplemental Table 1 for the 
residue boundaries. Fl: fluorescein. d, Cell-based assay showing that Mig6 inhibits full-
length EGFR autophosphorylation, whereas mutations in segment 1 abolishes the inhibition.
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Figure 3. Inhibition of the EGFR kinase activity by Mig6segment 1–2
a, Inhibition of the L834R mutant kinase in solution by peptides 336–412, 336–412(Y358A) 
(containing both segment 1 and 2). The 30-residue peptide (containing segment 1 only) is 
used as a control. The insert shows an expanded view at low peptide concentrations. b, 
Inhibition of the wild type kinase in solution by peptides 336–412 and 336–412(Y358A). 
Titration of peptide 336–412 beyond 20 μM leads to unreliable results due to precipitation of 
the protein and peptide (See Method).
Zhang et al. Page 10









Figure 4. A double-headed mechanism for EGFR inhibition by Mig6
a, Co-transfection experiment showing that EGFRactivator can activate EGFRactivatable, and 
that Mig6 can inhibit this activation. b, Co-transfection experiments showing that full-length 
EGFR containing the L834R/V924R double mutation only shows autophosphorylation when 
co-transfected with EGFRactivator. Co-transfection combinations in (a) and (b) are 
represented by the cartoons in the respective lower panels for clarity. The I682Q, D813N, 
L834R and V924R mutations are denoted in the cartoons by a circle, diamond, star and 
triangle, respectively. c, a schematic diagram showing the double-headed mechanism for 
EGFR inhibition by Mig6 involving both segment 1 and segment 2.
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